| 4.025 0.005 (0.12%) | 03-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.73 |
1-year : | 5.52 |
| Resists | First : | 4.05 |
Second : | 4.73 |
| Pivot price | 3.93 |
|||
| Supports | First : | 3.92 |
Second : | 3.83 |
| MAs | MA(5) : | 4.01 |
MA(20) : | 3.93 |
| MA(100) : | 3.77 |
MA(250) : | 3.2 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 92.5  |
D(3) : | 93.4 |
| RSI | RSI(14): 70.4 |
|||
| 52-week | High : | 4.05 | Low : | 2.08 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GTH ] has closed below upper band by 17.4%. Bollinger Bands are 83.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.05 - 4.07 | 4.07 - 4.09 |
| Low: | 3.97 - 4 | 4 - 4.02 |
| Close: | 3.99 - 4.03 | 4.03 - 4.06 |
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Tue, 23 Apr 2024
Genetron (NASDAQ:GTH) Trading 0.2% Higher - Defense World
Sat, 30 Mar 2024
Genetron Holdings Limited (NASDAQ:GTH) Short Interest Update - MarketBeat
Tue, 09 Jan 2024
Genetron Holdings' Enticing Arbitrage Return (NASDAQ:GTH) - Seeking Alpha
Thu, 05 May 2022
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
Mon, 26 Jul 2021
Genetron Holdings Ltd - ADR (GTH) Stock Falls -11.93% This Week: Is It a Good Pick? - InvestorsObserver
Wed, 20 Jan 2021
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 32 (M) |
| Shares Float | 215 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 12.5 (%) |
| Shares Short | 21 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | -3.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.89 |
| Profit Margin | -124.3 % |
| Operating Margin | -87.5 % |
| Return on Assets (ttm) | -35.3 % |
| Return on Equity (ttm) | -92.2 % |
| Qtrly Rev. Growth | 37 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 20.57 |
| EBITDA (p.s.) | -20.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -460 (M) |
| Levered Free Cash Flow | -318 (M) |
| PE Ratio | -1.12 |
| PEG Ratio | 0 |
| Price to Book value | 0.22 |
| Price to Sales | 0.19 |
| Price to Cash Flow | -0.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|